HOLX Hologic, Inc.

Price (delayed)

$65.79

Market cap

$17.04B

P/E Ratio

34.99

Dividend/share

N/A

EPS

$1.88

Enterprise value

$19.61B

Sector: Healthcare
Industry: Medical Instruments & Supplies
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.

Highlights

Hologic's quick ratio has increased by 16% QoQ and by 9% YoY
Hologic's gross margin has increased by 16% YoY and by 2.4% QoQ
The company's debt rose by 8% YoY but it fell by 7% QoQ

Key stats

What are the main financial stats of HOLX
Market
Shares outstanding
258.99M
Market cap
$17.04B
Enterprise value
$19.61B
Valuations
Price to earnings (P/E)
34.99
Price to book (P/B)
7.53
Price to sales (P/S)
5.19
EV/EBIT
50.08
EV/EBITDA
24.93
EV/Sales
5.95
Earnings
Revenue
$3.3B
EBIT
$391.6M
EBITDA
$786.7M
Free cash flow
$572.8M
Per share
EPS
$1.88
Free cash flow per share
$2.2
Book value per share
$8.73
Revenue per share
$12.68
TBVPS
$11.38
Balance sheet
Total assets
$6.8B
Total liabilities
$4.54B
Debt
$3.32B
Equity
$2.26B
Working capital
$637.1M
Liquidity
Debt to equity
1.47
Current ratio
1.47
Quick ratio
1.09
Net debt/EBITDA
3.27
Margins
EBITDA margin
23.9%
Gross margin
46.9%
Net margin
15.1%
Operating margin
11.7%
Efficiency
Return on assets
7.5%
Return on equity
22.8%
Return on invested capital
9.7%
Return on capital employed
7.2%
Return on sales
11.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HOLX stock price

How has the Hologic stock price performed over time

Financial performance

How have Hologic's revenue and profit performed over time
Revenue
$3.3B
Gross profit
$1.55B
Operating income
$385.7M
Net income
$496.8M
Gross margin
46.9%
Net margin
15.1%
Hologic's gross margin has increased by 16% YoY and by 2.4% QoQ
The gross profit has grown by 15% YoY
The operating margin has grown by 15% from the previous quarter
Hologic's operating income has increased by 13% QoQ

Valuation

What is Hologic stock price valuation
P/E
34.99
P/B
7.53
P/S
5.19
EV/EBIT
50.08
EV/EBITDA
24.93
EV/Sales
5.95
The EPS is up by 11% since the previous quarter
HOLX's price to book (P/B) is 51% higher than its 5-year quarterly average of 5.0 and 32% higher than its last 4 quarters average of 5.7
HOLX's equity is up by 8% since the previous quarter
HOLX's price to sales (P/S) is 40% higher than its 5-year quarterly average of 3.7 and 40% higher than its last 4 quarters average of 3.7

Efficiency

How efficient is Hologic business performance
The return on sales is up by 16% since the previous quarter
HOLX's return on invested capital is up by 12% since the previous quarter
The ROE has grown by 9% from the previous quarter
Hologic's return on assets has increased by 9% QoQ

Dividends

What is HOLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOLX.

Financial health

How did Hologic financials performed over time
The total assets is 50% higher than the total liabilities
Hologic's quick ratio has increased by 16% QoQ and by 9% YoY
Hologic's current ratio has increased by 12% from the previous quarter but it has decreased by 6% YoY
The company's debt is 47% higher than its equity
Hologic's debt to equity has decreased by 14% from the previous quarter but it has increased by 6% YoY
The company's debt rose by 8% YoY but it fell by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.